Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Mirko V Sikirica,1 Alan A Martin,2 Robert Wood,3 Andrea Leith,3 James Piercy,3 Victoria Higgins3 1Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 2Value Evidence and Outcomes, GlaxoSmithKline, London, UK; 3Diabetes, Adelphi Real World, Bollington, Cheshire, UK Aim: Nonadherence...

Full description

Bibliographic Details
Main Authors: Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V
Format: Article
Language:English
Published: Dove Medical Press 2017-09-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
antidiabetic drug
cross-sectional survey
discontinuation
incretins
incretin therapy
glycemic control
Online Access:https://www.dovepress.com/reasons-for-discontinuation-of-glp1-receptor-agonists-data-from-a-real-peer-reviewed-article-DMSO

Internet

https://www.dovepress.com/reasons-for-discontinuation-of-glp1-receptor-agonists-data-from-a-real-peer-reviewed-article-DMSO

Similar Items